Cargando…
Successful osimertinib retreatment after extremely early onset severe pneumonitis in first‐line treatment of lung adenocarcinoma
Drug‐induced pneumonitis is rare, and can result in death. Here, we present a report of a patient with adenocarcinoma harboring EGFR exon 19 deletion mutation treated with osimertinib as first‐line treatment. After six days of treatment, extremely early onset severe pneumonitis was diagnosed. Discon...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons Australia, Ltd
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471046/ https://www.ncbi.nlm.nih.gov/pubmed/32666714 http://dx.doi.org/10.1111/1759-7714.13565 |